Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

Huntington's disease: brain abnormalities detectable as early as the embryonic stage

Published on: 17/07/2020 Reading time: 1 min
image
Retour à la recherche

Huntington's disease is a genetic neurological disorder that generally appears in adulthood. Teams of researchers and clinicians at the Grenoble Institute of Neuroscience (Inserm/Grenoble Alpes University) and the Brain Institute (Inserm/Sorbonne University/CNRS/AP-HP) have discovered cerebral abnormalities in the brains of human embryos carrying the mutation responsible for Huntington's disease. This work, to be published in Science, raises questions about the mechanisms of silent progression of the disease, and when and how to treat patients in the future.

Although Huntington’s disease is a late-manifesting neurodegenerative disorder, both mouse studies and neuroimaging studies of presymptomatic mutation carriers suggest that Huntington’s disease might affect neurodevelopment. To determine whether this is actually the case, we examined tissue from human fetuses (13 weeks gestation) that carry the Huntington’s disease mutation. These tissues showed clear abnormalities in the developing cortex, including mislocalization of mutant huntingtin and junctional complex proteins, defects in neuroprogenitor cell polarity and differentiation, abnormal ciliogenesis, and changes in mitosis and cell cycle progression. We observed the same phenomena in Huntington’s disease mouse embryos, where we linked these abnormalities to defects in interkinetic nuclear migration of progenitor cells. Huntington’s disease thus has a neurodevelopmental component and is not solely a degenerative disease.

« C’est la première fois que des anomalies du développement cérébral sont mises en évidence dans cette maladie. De plus, celles-ci sont relativement importantes et étendues bien que nous ne soyons pas encore capables de déterminer leurs conséquences directes », clarifient Sandrine Humbert et Alexandra Durr qui ont dirigé ces travaux.

Mais pourquoi les porteurs de la mutation ne manifestent-ils alors aucun symptôme avant un âge avancé ? « À ce stade, nous posons l’hypothèse que le cerveau met très tôt en place des mécanismes de compensation qui permettent un fonctionnement normal. Il se pourrait d’ailleurs qu’il en soit de même chez les personnes porteuses de mutations associées à d’autres types de dégénérescence comme la maladie d’Alzheimer ou la sclérose latérale amyotrophique », précisent les chercheuses.

auteur à supprimer

Celles-ci vont maintenant poursuivre la description du développement cérébral chez des souris modèles de la maladie de Huntington, tenter de comprendre comment ces défauts précoces contribuent à la pathologie adulte, et comment la compensation de ces derniers pourrait être régulée pendant toute la période silencieuse sans symptômes. « Cette découverte a en outre des conséquences importantes sur la façon et le stade auxquels les traitements qui modifient le cours de la maladie doivent désormais être envisagés », concluent-elles.

auteur à supprimer

Sources

https://science.sciencemag.org/content/early/2020/07/15/science.aax3338

Our news on the subject

Sclérose en plaques : identification d’une nouvelle molécule favorisant la remyélinisation
Multiple Sclerosis: Identification of a Molecule that Promotes Repair of the Nervous System
A molecule previously studied in the context of sleep disorders and attention deficit hyperactivity disorder (ADHD) is now, for the first time, revealing its potential in experimental models of multiple sclerosis (MS): it protects neurons and...
01.27.2026 Research, science & health
VignetteActu WBHF 2026
World Brain Health Forum 2026
More than one in three people will experience a brain disorder at some point in their lives. This reality, identified by the World Health Organization as a major public health priority, calls for unprecedented international mobilization. It is...
01.12.2026 Events
Une nouvelle approche pour évaluer les patients en état de conscience altérée
A New Approach to Assessing Patients with Disorders of Consciousness
In intensive care units, some patients who appear unconscious occupy a gray zone in their relationship to the world. To better diagnose them and predict their recovery potential, Dragana Manasova, Jacobo Sitt, and their colleagues have developed an...
01.08.2026 Research, science & health
Ne plus penser à rien : vers une signature cérébrale du blanc mental
Not Thinking About Anything: Toward a Brain Signature of Mind Blanking
What if the flow of our thoughts occasionally just stopped? Esteban Munoz-Musat, Lionel Naccache, Thomas Andrillon, and their colleagues at Paris Brain Institute and Monash University in Melbourne show that the sensation of “thinking about nothing”...
12.26.2025 Research, science & health
Deux nouvelles certifications pour les plateformes de l’Institut du Cerveau
Two new certifications for Paris Brain Institute’s core facilities
Paris Brain Institute’s core facilities were recently awarded two new certifications: ISO 9001 certification for ICM.Quant and ISO 20387 certification for its DNA & Cell Bank.
11.14.2025 Institutional
La dépression résistante possède une signature moléculaire spécifique
Treatment-resistant depression identified as a distinct molecular subtype
An international study published in Brain, Behavior, and Immunity shows that patients with treatment-resistant depression (TRD) have a unique biology, different from those who respond to standard therapies. More than 5,000 genes were found to behave...
11.03.2025 Research, science & health
See all our news